BVAXF
Biovaxys Technology Corp

516
Mkt Cap
$1.48M
Volume
13,636.00
52W High
$0.40
52W Low
$0.029
PE Ratio
-0.32
BVAXF Fundamentals
Price
$0.0508
Prev Close
$0.0508
Open
$0.0422
50D MA
$0.0993
Beta
-0.21
Avg. Volume
84,153.91
P/B
-0.56
Loading...
Loading...

About

BioVaxys Technology Corp. is a clinical stage biotechnology company. It engages in developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The firm is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is preparing for a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. The company was founded by James Christopher Passin, Kenneth E. Kovan and David Berd on April 25, 2018 and is headquartered in Etobicoke, Canada.
Sector:
Non Energy Minerals
Industry:
Other Metals Or Minerals
Employees:
N/A

Frequently Asked Questions

What is Market Cap of BioVaxys Technology Corp?
What is the 52-week high for BioVaxys Technology Corp?
What is the 52-week low for BioVaxys Technology Corp?
What is BioVaxys Technology Corp stock price today?
What was BioVaxys Technology Corp stock price yesterday?
What is the PE ratio of BioVaxys Technology Corp?
What is the Price-to-Book ratio of BioVaxys Technology Corp?
What is the 50-day moving average of BioVaxys Technology Corp?

Latest BVAXF News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.